|drug1090||Double-Blind NT-I7 Wiki||1.00|
|drug1091||Double-Blind Placebo Wiki||1.00|
There is one clinical trial.
The goal of the study is to examine whether a shared decision making intervention improves decision making about colon cancer screening for patients who had their colonoscopy delayed or postponed due to the COVID pandemic. Eligible patients (n=800) will be randomly assigned to either the intervention or control arm. A subset will be surveyed about 6 weeks post intervention to measure shared decision making, their intention to follow through with screening, and their decisional conflict. Study staff will conduct medical chart review to track receipt of colon cancer screening within 6 months. The statistician will test whether patients in the intervention arm report more shared decision making, less decisional conflict, higher intention to follow through on screening and have higher screening rates compared to those in the control arm.
Description: short patient reported scale asks patients about discussion of options, pros and cons of colonoscopy and discussion of patients' preferences. Total scores range from 0-4 with higher scores indicating higher shared decision making.Measure: Shared Decision Making (SDM) Process Scale Score Time: 6 weeks after intervention
Description: the 4-item version of the decisional conflict scale, total score ranges from 0-4 with greater scores indicating less decisional conflict.Measure: Decisional Conflict (SURE scale) Time: 6 weeks after intervention
Description: One item will assess patients' preferred approach to screening (with responses of colonoscopy, stool card test, no screening, not sure).Measure: Patient's preferred approach to screening Time: 6 weeks after intervention
Description: One item will assess patients' intention to follow through with their preferred approach on a 5-point scale from not at all likely to extremely likely.Measure: Intention to screen Time: 6 weeks after intervention
Description: Percentage of patients who had completed colon cancer screening testMeasure: Colon cancer screening rate Time: 6 months after randomization
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports